MS News That Caught My Eye Last Week: Ublituximab, ATA188, COVID-19, Cognitive Rehab

MS News That Caught My Eye Last Week: Ublituximab, ATA188, COVID-19, Cognitive Rehab

308115

MS News That Caught My Eye Last Week: Ublituximab, ATA188, COVID-19, Cognitive Rehab

Ublituximab, Potential Relapsing MS Therapy, Up for FDA Approval Like Ocrevus (ocrelizumab) and Kesimpta (ofatumumab), ublituximab targets the CD20 protein that’s found on the surface of B-cells in the immune system. It then binds to it and kills the cell, reducing the number of cells that are attacking the nerve fibers of people with MS. Unlike other antibody medications, however, ublituximab is designed without certain sugar molecules. Removing those sugars increases the medication’s potency, so…

You must be logged in to read/download the full post.